IL2 and neoplasm: We have previously shown that the usage of the immune-stimulating immunocytokine FAP-IL-2v specifically binding fibroblast activation protein α (FAP) on tumor cell stroma and tumor-infiltrating MDSCs, via the FAP moiety of the immunocytokine, and that selectively activating NK cells via the mutated variant of IL-2, linked to the FAP fragment without the induction of Treg, resulted in a significant improvement in immunotherapy with DB [3].